Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, ...

- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA ...

SAN FRANCISCO, October 09, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial ...

GSK and Vir Biotechnology struck up their influenza R&D collaboration three years ago, aiming to build on a respiratory drug relationship forged at the start of the Covid-19 pandemic. The British ...

CEO Marianne De Backer highlighted the completion of enrollment in ECLIPSE 1, Vir’s first registrational Phase III study for hepatitis delta, ahead of internal projections. She indicated that "we now ...

– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage ...

Vir Biotechnology, Inc. (NASDAQ:VIR), currently trading at $5.02, has seen its stock decline over 34% year-to-date, reflecting investor concerns despite its potential in treating serious infectious ...

Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab in a variety of EGFR-expressing solid tumors such ...

SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase 1 ...

Vir Biotechnology, Inc. VIR shares rallied 15.1% in the last trading session to close at $40.01. This move can be attributable to notable volume with a higher number of shares being traded than in a ...